INT144068

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.48
First Reported 2007
Last Reported 2010
Negated 0
Speculated 0
Reported most in Abstract
Documents 9
Total Number 9
Disease Relevance 7.67
Pain Relevance 3.16

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

transport (Nsf) vesicle-mediated transport (Nsf) ATPase activity (Nsf)
plasma membrane (Nsf) cytoplasm (Nsf)
Nsf (Mus musculus)
Pain Link Frequency Relevance Heat
fibrosis 233 100.00 Very High Very High Very High
imagery 20 98.04 Very High Very High Very High
Pain 9 96.24 Very High Very High Very High
nMDA receptor 3 88.84 High High
Inflammation 10 87.44 High High
Glutamate receptor 9 61.20 Quite High
Neurotransmitter 4 5.00 Very Low Very Low Very Low
long-term potentiation 3 5.00 Very Low Very Low Very Low
Glutamate 3 5.00 Very Low Very Low Very Low
Calcium channel 3 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Nephrogenic Fibrosing Dermopathy 236 100.00 Very High Very High Very High
Disease 29 100.00 Very High Very High Very High
Renal Insufficiency 5 97.48 Very High Very High Very High
Chronic Renal Failure 54 96.44 Very High Very High Very High
Pain 7 96.24 Very High Very High Very High
INFLAMMATION 10 87.44 High High
Contracture 5 83.28 Quite High
Sclerosis 1 81.76 Quite High
Renal Failure 12 81.40 Quite High
Renal Disease 21 79.96 Quite High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
In this short review, the development of NSF and its sequential association with the exposure to gadolinium-containing contrast agents is presented.
NSF Binding (association) of associated with fibrosis
1) Confidence 0.48 Published 2007 Journal Kidney Int. Section Abstract Doc Link 17507905 Disease Relevance 0.71 Pain Relevance 0.34
Discussed are the possible association of Gd3+-based contrast media with the development of NSF and potential for the use of sodium thiosulfate in the treatment of NSF.
NSF Binding (association) of associated with fibrosis
2) Confidence 0.36 Published 2007 Journal Clinical journal of the American Society of Nephrology : CJASN Section Abstract Doc Link 17699422 Disease Relevance 1.09 Pain Relevance 0.45
PSD-95 expression affects AMPA receptor-mediated excitatory synaptic transmission (Migaud et al, 1998; Beique et al, 2006; Carlisle et al, 2008) and is thought to involve indirect interactions through stargazin, SAP-97, Adam22, Lgi1 and Nsf (Leonard et al, 1998; Osten et al, 1998; Fukata et al, 2006).
Nsf Binding (interactions) of
3) Confidence 0.25 Published 2009 Journal Mol Syst Biol Section Body Doc Link PMC2694677 Disease Relevance 0.15 Pain Relevance 0.08
In 43 of these the NSF was linked to gadodiamide; in 6 to gadopentetate dimeglumine (Magnevist; Berlex Imaging, Montville, N.J.); in 2 to gadoversetamide (OptiMARK; Mallinckrodt, St.
NSF Binding (linked) of associated with fibrosis and imagery
4) Confidence 0.23 Published 2007 Journal Pediatr Radiol Section Body Doc Link PMC2292494 Disease Relevance 1.01 Pain Relevance 0.47
Nephrogenic systemic fibrosis (NSF; formerly named nephrogenic fibrosing dermopathy) is a systemic disease that was first described in 1997 and recognized as a separate clinical entity in 2000 [1–4].
NSF Binding (recognized) of associated with nephrogenic fibrosing dermopathy, fibrosis and disease
5) Confidence 0.22 Published 2007 Journal Pediatr Radiol Section Body Doc Link PMC2292494 Disease Relevance 1.05 Pain Relevance 0.23
Sadowski et al. [26] also reported one patient with confirmed NSF associated with both gadodiamide and gadobenate dimeglumine (MultiHance, Bracco Diagnostics, Milan, Italy).
NSF Binding (associated) of associated with fibrosis
6) Confidence 0.22 Published 2007 Journal Pediatr Radiol Section Body Doc Link PMC2292494 Disease Relevance 0.85 Pain Relevance 0.47
The pathogenesis of the disease is not known yet, but recently we suggested a strong association between development of NSF and exposure to gadolinium-based contrast (GBC) agents, thereafter confirmed by other authors.
NSF Binding (association) of associated with fibrosis and disease
7) Confidence 0.21 Published 2008 Journal Semin Dial Section Abstract Doc Link 18226001 Disease Relevance 1.09 Pain Relevance 0.46
The purpose of this study was to explore the plausibility of a gadolinium linkage with NSF as well as to assess the efficacy of ECP in the treatment of a cohort of patients with NSF.
NSF Binding (linkage) of associated with fibrosis
8) Confidence 0.18 Published 2007 Journal Arch Dermatol Section Abstract Doc Link 17709661 Disease Relevance 0.92 Pain Relevance 0.34
Exposure to gadolinium-based contrast agents (GdCA) has been associated with the development of NSF.
NSF Binding (associated) of associated with fibrosis
9) Confidence 0.11 Published 2010 Journal J. Am. Acad. Dermatol. Section Abstract Doc Link 20115955 Disease Relevance 0.81 Pain Relevance 0.33

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox